Problem drug use and dependence are neurobehavioral disorders of complex origin. Although environmental factors contribute to drug abuse and addiction, genetic factors also play a significant role estimated at 40 -60% of the total risk. Nonetheless, the precise identities of human genes that confer vulnerability to problem drug use remain mostly unknown. Here, we describe a natural single nucleotide polymorphism in the human gene that encodes the principal endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), that in homozygous form is strongly associated with both street drug use and problem drug͞alcohol use. This single nucleotide polymorphism results in a missense mutation (385C3 A) that converts a conserved proline residue to threonine (Pro1293 Thr), producing a FAAH variant that displays normal catalytic properties but an enhanced sensitivity to proteolytic degradation. Collectively, these results suggest that genetic mutations in FAAH may constitute important risk factors for problem drug use and support a potential link between functional abnormalities in the endogenous cannabinoid system and drug abuse and dependence. D rug abuse and dependence are neurobehavioral disorders of complex origin in which both environmental and genetic factors are perceived to contribute to vulnerability (1). Genetic factors have been estimated to account for 40-60% of the risk in susceptible individuals (2). Although the primary molecular sites of action for many drugs of abuse are well characterized, efforts to identify genetic alterations in these neural signaling systems that are associated with problem drug use and addiction have, to date, been mostly unsuccessful (2). One neural signaling pathway generally implicated in drug abuse and addiction is the endogenous cannabinoid system (3). This system includes a G protein-coupled receptor CB1 that binds the principal psychoactive component of marijuana, ⌬-9-tetrahydrocannabinol, and the putative endogenous CB1 ligands, anandamide and 2-arachidonoylglycerol (4). Recent evidence suggests that the endogenous cannabinoid system may contribute not only to the development of dependence on marijuana (5) but also other drugs of abuse (6-8). Mice with a targeted disruption in the CB1 receptor exhibit reduced withdrawal responses to morphine (9), suggesting that significant crosstalk exists between endogenous opioid and cannabinoid systems in neural pathways that mediate addiction. Consistent with this notion, withdrawal from cannabinoids is significantly reduced in mice lacking preproenkephalin (10) or the -opioid receptor (11).
D
rug abuse and dependence are neurobehavioral disorders of complex origin in which both environmental and genetic factors are perceived to contribute to vulnerability (1) . Genetic factors have been estimated to account for 40-60% of the risk in susceptible individuals (2) . Although the primary molecular sites of action for many drugs of abuse are well characterized, efforts to identify genetic alterations in these neural signaling systems that are associated with problem drug use and addiction have, to date, been mostly unsuccessful (2) . One neural signaling pathway generally implicated in drug abuse and addiction is the endogenous cannabinoid system (3) . This system includes a G protein-coupled receptor CB1 that binds the principal psychoactive component of marijuana, ⌬-9-tetrahydrocannabinol, and the putative endogenous CB1 ligands, anandamide and 2-arachidonoylglycerol (4) . Recent evidence suggests that the endogenous cannabinoid system may contribute not only to the development of dependence on marijuana (5) but also other drugs of abuse (6) (7) (8) . Mice with a targeted disruption in the CB1 receptor exhibit reduced withdrawal responses to morphine (9) , suggesting that significant crosstalk exists between endogenous opioid and cannabinoid systems in neural pathways that mediate addiction. Consistent with this notion, withdrawal from cannabinoids is significantly reduced in mice lacking preproenkephalin (10) or the -opioid receptor (11) .
Recently, a third central component of the endogenous cannabinoid system, the integral membrane enzyme fatty acid amide hydrolase (FAAH), has been identified (12) (13) (14) . Several lines of evidence suggest that FAAH serves as a primary catabolic regulator of anandamide and related fatty acid amide-signaling molecules in vivo. Specifically, mice with a targeted disruption in the FAAH gene (FAAH Ϫ/Ϫ ) are severely impaired in their ability to degrade anandamide and exhibit exaggerated behavioral responses to this fatty acid amide, including hypomotility, hypothermia, analgesia, and catalepsy (15) . Moreover, endogenous brain levels of anandamide and related fatty acid amides are increased over 10-fold in FAAH Ϫ/Ϫ mice, correlating with enhanced CB1-dependent analgesia in these animals (15) . Collectively, these findings suggest that FAAH may control the magnitude and duration of fatty acid amide signaling in vivo by setting an endocannabinoid tone in the brain as well as possibly in other parts of the nervous system. Because it is known that exogenous cannabinoids influence the sensitivity or vulnerability to other drugs of abuse in both humans and mammals (6, 8, 16) , we interpreted the neurobehavioral and neurochemical abnormalities in FAAH Ϫ/Ϫ mice as circumstantial evidence that mutations in the human FAAH gene may result in dysregulation of endogenous cannabinoid signaling and, thereby produce alterations in brain addiction͞reward pathways that could ultimately influence drug use. To explore this hypothesis, we conducted a search for mutations in the human FAAH gene in subjects with several neurobehavioral disorders, including street drug use and problem drug or alcohol use.
Materials and Methods
FAAH Gene Sequencing and PCR Amplification. Oligonucleotide primers and PCR conditions were designed for each of the 15 FAAH exons. Each exon was completely sequenced with patient and control DNA samples for a total of 1,550 sequences. Single nucleotide polymorphisms (SNPs), or microsatellite repeats occurring in more than 1% of samples, were evaluated for predicted amino acid change in the mature protein and for alternative splice sites. SNPs were confirmed by comparison with two SNP databases and numbered based on the predicted ATG start site of the human FAAH cDNA (the ATG was considered bases 1-3). The FAAH SNP cDNA 385A was identified as potentially significant because this polymorphism predicts the conversion of Pro residue 129, conserved in all mammalian FAAH proteins sequenced to date (human, mouse, rat, pig, and cow), to Thr. Therefore, the cytosine 385 to adenosine (385C3A) missense mutation was selected for further study; because the gene frequency of the C allele is the highest, it is designated throughout as the wild type (wt).
Research Subjects. Patients attending a medical screening clinic were invited to participate with informed consent in DNA screening for genetic disorders. Each subject in this study (Study A) completed a comprehensive health appraisal questionnaire that was linked to the subject's DNA sample. DNA samples and clinical data for this study were from sources not known to the examiner. For Study A subjects, the questionnaire variables that were retained included age, sex, ancestral origin, the presence of medical disorders and neuropsychiatric disorders such as anxiety, depression symptoms, suicidal feelings, history of street drug use, serious problems with drug or alcohol use, nicotine use, and alcohol use. This allowed stratification of variables into groups of patients and matching controls. Patient DNA samples from Study A selected for FAAH 385C3A genotype analysis were all of white ancestral origin because of under-representation of with Yates correction, relative risk [with 95% confidence interval (CI)] and odds ratio (with 95% CI) on 2 ϫ 2 and 2 ϫ 3 contingency tables. Significant P values were corrected for 10 group comparisons by the Bonferroni method.
Expression and Purification of Rat and Human FAAH Variants. The 385C3A point mutation was introduced into both the human and rat FAAH cDNA sequences by using Stratagene QuickChange procedures and was validated by sequencing. Wild-type and Pro-1293Thr (P129T) mutant rat FAAH enzymes were expressed as N-terminal His-6-fusion proteins in Escherichia coli lacking the N-terminal transmembrane domain of the wild-type protein (⌬TM-FAAH), as described (18) . Pure FAAH protein (Ϸ1.0 mg) was isolated per liter of culture volume for both the wild-type and ⌬TM-FAAH variants. Wild-type and P129T human FAAH variants were expressed as full-length proteins by transient transfection in COS-7 cells, as described (13) .
FAAH Catalytic Activity Assays. The rates of FAAH-catalyzed hydrolysis of oleamide and anandamide were determined by using 14 C-labeled substrates and purified rat ⌬TM-FAAH variants, as described (18) . K m and k cat values were determined from Lineweaver-Burk plots of six substrate concentrations performed in triplicate. Heat-inactivation assays were conducted with human FAAH variants expressed in COS-7 cells. COS-7 cells transiently transfected with either FAAH variant exhibited over 100-fold higher FAAH activity than cells transfected with empty vector, with the wild-type protein expressing to approximately two-fold higher levels than the P129T variant (as judged by relative oleamide hydrolysis activities and Western blotting with anti-FAAH antibodies). Samples of transfected COS-7 membrane extracts were incubated for 30 min at one of seven different temperatures ranging from 37 to 55°C, after which the samples were cooled to room temperature; FAAH activity was then measured in triplicate (60 min reaction at 37°C with 100 M [ 14 C]oleamide; reaction buffer, 50 mM Tris͞125 mM NaCl, pH 8.0).
Urea Denaturation Curves of Wild-Type and P129T FAAH Variants.
The stability of purified wild-type and P129T rat ⌬TM-FAAH variants was measured as a function of urea concentration in 50 mM phosphate buffer at pH 7.5. Each protein (0.15 mg͞ml) was incubated for 24 h with freshly prepared solutions of urea, with final urea concentrations ranging from 0 to 9.75 M. The tryptophan fluorescence spectra of each FAAH variant was recorded over the range of 310-410 nm by using an ATF 105 Aviv spectrofluorometer equipped with a thermostated cell holder employing excitation at 295 nm. Native FAAH proteins exhibited a fluorescence maximum at 335-340 nm, whereas unfolded proteins showed maximum emissions between 350 and 355 nm. The 350͞340 nm emission intensity ratio was used to follow the denaturation of each FAAH variant as a function of urea concentration.
Far UV-Circular Dichroism Spectrometry of Wild-Type and P129T FAAH
Variants. Purified wild-type and P129T rat ⌬TM-FAAH samples were diluted to a concentration of 0.4 mg͞ml and their respective circular dichroism (CD) spectra obtained with an Aviv stoppedflow CD spectrometer, as described (19) .
Trypsin Sensitivity of Wild-Type and P129T FAAH Variants. Wild-type and P129T human FAAH-transfected COS-7 cell membranes normalized for equal FAAH levels were treated with trypsin (5 M final concentration; Sigma) and incubated at 30°C (reaction The statements or questions represent the exact wording in the questionnaire completed by all patients in the groups shown. When more than one question is listed, an affirmative answer to any one question was regarded as positive in that category. *Drug͞Alcohol problem users included together because there was no separate questionnaire category for each; alcohol users with no drug use were analyzed separately.
buffer, 50 mM Tris͞125 mM NaCl, pH 8.0). At six time points, ranging from 5 to 60 min, reactions were terminated by the addition of soybean trypsin inhibitor (15 M final concentration; Sigma). Samples then were divided into two fractions for the analysis of FAAH protein levels. One set of fractions was analyzed by Western blotting by using anti-FAAH polyclonal antibodies, as described (13) . The second set of fractions was treated with a rhodamine-tagged active site-directed probe, FP-rhodamine, for 30 min at room temperature, following published methods (20, 21 
Results

FAAH 385A͞385A Homozygous State Is Associated with Street Drug
Use and Drug͞Alcohol Abuse. In the first data analysis, the frequencies of the mutant 385A allele in the white problem drug or alcohol user group (n ϭ 80) and white control group I composed of subjects denying street drug use and problem drug or alcohol use (n ϭ 1737) were 0.256 and 0.1796, respectively. These allele frequencies differed significantly (Fisher's exact test, P ϭ 0.0190). The allele frequency of the same white problem drug or alcohol user group (n ϭ 80) also differed significantly from control group II composed of white neuropsychologically normal subjects denying street drug use and problem drug or alcohol use (n ϭ 1144; Fisher's exact test, P ϭ 0.0408).
A more detailed analysis of the occurrence of the FAAH cDNA 385A SNP revealed that 385A͞wt heterozygotes were not overrepresented in the street drug user or problem drug͞alcohol user groups relative to the distribution of the wt͞wt FAAH genotype (Table 2 ). In contrast, comparisons of 385A͞385A individuals with wt͞wt individuals or pooled groups containing the 385A͞wt and wt͞wt genotypes revealed a strong and selective association of the 385A͞385A genotype with street drug use and problem drug͞alcohol use (Table 2 and Fig. 1 ; P ϭ 0.0001). The odds ratio for risk of problem drug or alcohol use in individuals with the 385A͞385A homozygous genotype was 4.5, with a 95% CI between 2.2 and 8.4 (Table 2 and Fig. 2) . Similarly, the odds ratio for risk of street drug use in 385A͞385A individuals was 2.2 (95% CI, 1.3-3.7; Table 2 and Fig. 2) . Finally, the odds ratio for risk of combined street drug use and problem drug͞alcohol use in 385A͞385A individuals was 4.9 (95% CI, 2.5-9.7; Table 2 and Fig. 2 ).
Generation and Initial Characterization of Wild-Type and P129T Mutant FAAH Proteins.
To study the effects of the P129T mutation on the catalytic and structural properties of FAAH, this mutation was introduced into both the rat and human FAAH proteins. Proline129 resides in a region of primary structure that is highly conserved between the rat and human FAAH proteins (complete sequence identity from amino acids 120-145), indicating that both species variants should represent acceptable models for investigating the biochemical effects of the mutation of this residue. However, rat FAAH variants offer the advantage of superior recombinant expression in E. coli (data not shown); therefore, wild-type and P129T rat FAAH proteins were used for biochemical and biophysical studies that required large quantities of pure protein. In contrast, for experiments that were compatible with unpurified protein preparations, we examined Wild-type and P129T rat FAAH proteins were expressed in E. coli as His-6-tagged fusion proteins lacking the predicted Nterminal FAAH transmembrane domain (⌬TM-FAAH proteins) and purified as described in Materials and Methods. Deletion of the N-terminal transmembrane domain of FAAH has been shown to assist in the expression and purification of the enzyme without affecting its general catalytic properties (18) . Purified wild-type and P129T FAAH proteins were found to display equivalent gel filtration elution profiles and UV CD spectra (data not shown), indicating that the quaternary and tertiary structures of FAAH were not dramatically altered by the P129T mutation. Both wild-type and P129T FAAH proteins also exhibited similar K m and k cat values for the hydrolysis of two representative endogenous fatty acid amide substrates, oleamide and anandamide (Table 3 ), indicating that the P129T mutation did not significantly impact the catalytic properties of the enzyme.
Relative Structural Stabilities of Wild-Type and P129T Mutant FAAH
Proteins. The global structural stabilities of wild-type and P129T rat FAAH proteins were compared by determining their respective urea denaturation curves over a concentration of urea ranging from 0 to 9.5 M. Wild-type and P129T FAAH proteins exhibited similar urea denaturation curves (data not shown) and midpoint of denaturation values (7.4 M urea), suggesting that global protein stability was not altered by the P129T mutation. Consistent with this notion, wild-type and P129T variants of human FAAH expressed in COS-7 cells were found to exhibit similar heat-inactivation profiles (Fig. 3A) .
To evaluate the effect of the P129T mutation on the local structure of FAAH, the relative protease sensitivities of the wild-type and P129T human FAAH variants were compared by using a combination of Western blotting with anti-FAAH antibodies and chemical labeling with a fluorescent active sitedirected probe (FP-rhodamine; ref. 21) . By either method, the P129T FAAH protein was found to exhibit a significantly greater sensitivity to degradation by the protease trypsin (Fig. 3B) . A quantitative comparison of the fluorescence intensities of FPrhodamine-labeled wild-type and P129T FAAH proteins revealed that nearly 80% of the latter protein was proteolyzed after a 10-min incubation with trypsin, whereas only 40% of wild-type FAAH had been degraded at this time point (Fig. 3B) . Likewise, significant levels of wild-type FAAH protein, but not the P129T mutant, could be detected by Western blotting and FPrhodamine-labeling after a 40-60 min incubation with trypsin (Fig. 3B Inset) .
Discussion
The role of genetic factors in vulnerability to drug use and addiction is currently a topic of major interest. In particular, familial, twin, and adoption studies support a significant genetic contribution to addiction (1, 2). The identification of genetic abnormalities that contribute to the individual risk of drug use and addiction may provide new molecular targets for screening, prevention and treatment of these disorders.
Here, we report a naturally occurring single nucleotide polymorphism in the human FAAH gene, 385A, that is strongly associated with street drug use and problem drug͞alcohol use. This association seems especially relevant to illegal drug use, because neither alcohol nor nicotine abuse alone showed any significant relationship to the 385C3A missense mutation (Table 2). Moreover, we did not observe an association of the 385A SNP with any of the other neurobehavioral or neuropsychiatric disorders examined by our questionnaire, including depressive symptoms, suicidal ideation, schizophrenia, bipolar disorder, and autism.
FAAH is the primary catabolic regulator of a family of neuralsignaling molecules, the fatty acid amides, that includes the endogenous cannabinoid, anandamide (14) . Previous efforts to identify genetic relationships between the endogenous cannabinoid system and drug and alcohol abuse have focused on the analysis of the CB1 receptor gene and have produced mixed results. A frequent silent mutation in CB1 has been identified (1359G3A; ref. 22) , but its functional significance and relevance to drug and alcohol abuse remains controversial (23, 24) . In contrast, pharmacological studies have provided substantial evidence that activation of the cannabinoid system leads to key molecular and cellular changes associated with addiction. For example, cannabinoids have been shown to enhance mesolimbic dopaminergic transmission in a manner similar to heroin (25) . Likewise, long-term cannabinoid administration alters corticotropin-releasing factor activity, a neuroadaptive process generally related to drug dependence (26) .
Considering that the genetic deletion of FAAH in mice results in an adult mammal with greatly increased endogenous brain levels of anandamide and related fatty acid amides (15) , polymorphisms in the human FAAH gene that produce a functionally altered enzyme also might be expected to shift tonic levels of these signaling lipids. The FAAH SNP identified in this study produces a missense mutation (385C3A) that results in the conversion of a Pro residue to Thr (P129T). Interestingly, this Pro residue is completely conserved among all mammalian FAAH enzymes characterized to date, including the human, mouse, rat, pig, and bovine FAAH orthologues. Although the P129T mutation was not found to alter the general catalytic properties or structural stability of FAAH, it did produce a FAAH variant with significantly increased sensitivity to proteolytic degradation. Whether this enhanced protease sensitivity Fig. 2 . Distribution of odds ratios and 95% CIs for data analyses summarized in Table 3 . An odds ratio of 1 indicates that the probability of an individual with the homozygous mutation having the specific user trait indicated is no different from the probability of the genotype appearing in the control population. (15) . Although these findings are provocative in that they offer a potential link between functional alterations in the endogenous cannabinoid system and a predisposition to illegal drug use, alternative interpretations of the data are also possible. One confounding possibility is that of linkage disequilibrium, in which the FAAH 385C3A mutation would be linked to a nearby risk-determining gene mutation. Data interpretation also could be complicated by stratification bias inherent in the clinical grouping by questionnaire responses. However, clinical studies have demonstrated that a high rate of comorbidity exists between alcoholism and polydrug abuse (28) , indicating that these diseases may share a common molecular and cellular foundation. Finally, one must consider that addiction is a complex trait (1), and the FAAH cDNA 385C3A mutation is undoubtedly only one of many genetic and environmental factors that may influence the expression of the pathological phenotype. Nonetheless, the FAAH 385A͞385A genotype was sufficiently prevalent in street drug users and problem drug or alcohol users to detect above the background of many other genetic factors in the populations examined, and, therefore, may prove to be a useful diagnostic predictor of individuals at risk for drug-related disorders. More generally, the association of a naturally occurring human FAAH mutation with problem drug use provides further support that the endogenous cannabinoid system may play an important role in neural circuits that underlie drug abuse and dependence. 
